Akzo Nobel (OTCMKTS:AKZOY – Get Free Report) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 11,200 shares, a decline of 80.2% from the October 31st total of 56,700 shares. Based on an average daily trading volume, of 230,600 shares, the days-to-cover ratio is currently 0.0 days.
Akzo Nobel Stock Up 1.6 %
Akzo Nobel stock opened at $19.43 on Thursday. The company has a 50 day moving average of $21.71 and a 200-day moving average of $21.45. The company has a quick ratio of 0.89, a current ratio of 1.21 and a debt-to-equity ratio of 0.76. Akzo Nobel has a twelve month low of $19.08 and a twelve month high of $27.99. The stock has a market capitalization of $9.96 billion, a PE ratio of 19.24, a price-to-earnings-growth ratio of 0.68 and a beta of 1.30.
Akzo Nobel (OTCMKTS:AKZOY – Get Free Report) last released its earnings results on Wednesday, October 23rd. The basic materials company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04. The firm had revenue of $2.93 billion during the quarter, compared to analysts’ expectations of $3.01 billion. Akzo Nobel had a return on equity of 12.16% and a net margin of 4.47%. On average, equities research analysts anticipate that Akzo Nobel will post 1.45 EPS for the current fiscal year.
Akzo Nobel Cuts Dividend
About Akzo Nobel
Akzo Nobel N.V. engages in the production and sale of paints and coatings worldwide. The company operates through two segments: Decorative Paints and Performance Coatings. It offers decorative paints, including paints, lacquers, and varnishes; and a range of mixing machines and color concepts for the building and renovation industry, as well as specialty coatings.
Read More
- Five stocks we like better than Akzo Nobel
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Health Care Stocks Explained: Why You Might Want to Invest
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Small Caps With Big Return Potential
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Akzo Nobel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akzo Nobel and related companies with MarketBeat.com's FREE daily email newsletter.